secwatch / observer
8-K filed October 6, 2026, 4:15 PM ET ticker SLP CIK 0001023459
M&A confidence high sentiment neutral materiality 0.65

Simulations Plus closes $376.8M Altaris take-private at $18.50/share; combined with Chemical Computing Group

Simulations Plus, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. John K. Paglia

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
Appointed

Matteo Foderaro

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
Departed

Dr. Daniel Weiner

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
Appointed

Paul Labute

President
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
On October 6, 2026, following the consummation of the Merger, the Board appointed Paul Labute as President of the Company.
Departed

Dr. Walter S. Woltosz

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
Appointed

Charles Mullens

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
Departed

Sharlene Evans

Director
SLP · Simulations Plus, Inc.
Effective
2026-10-06
Filed
October 6, 2026, 4:15 PM ET
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. John K. Paglia departed as Director at Simulations Plus, Inc..

Action
ceased serving
Role
Director
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Matteo Foderaro was appointed as Director at Simulations Plus, Inc..

Action
became director
Role
Director
Exact text from the filing
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Daniel Weiner departed as Director at Simulations Plus, Inc..

Action
ceased serving
Role
Director
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Labute was appointed as President at Simulations Plus, Inc..

Action
appointed
Role
President
Exact text from the filing
On October 6, 2026, following the consummation of the Merger, the Board appointed Paul Labute as President of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Walter S. Woltosz departed as Director at Simulations Plus, Inc..

Action
ceased serving
Role
Director
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Mullens was appointed as Director at Simulations Plus, Inc..

Action
became director
Role
Director
Exact text from the filing
At the Effective Time, Matteo Foderaro and Charles Mullens became the directors of the Surviving Corporation.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sharlene Evans departed as Director at Simulations Plus, Inc..

Action
ceased serving
Role
Director
Exact text from the filing
Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dr. Daniel Weiner, Dr. Walter S. Woltosz, Dr. John K. Paglia and Sharlene Evans ceased serving as a member of the Board of Directors of the Company (the “ Board ”) and on any and all committees of the Board on which they served.
View on SEC.gov

Simulations Plus, Inc. filing history →

Source: SEC EDGAR
accession 0001023459-26-000092
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.